Skip to main content
Article thumbnail
Location of Repository

Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus

By Marjolijn CE Bragt, Jogchum Plat, Marco Mensink, Patrick Schrauwen and Ronald P Mensink
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2653037
Provided by: PubMed Central

Suggested articles

Citations

  1. (2004). Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation
  2. (1998). B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature
  3. (2004). BK: Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans.
  4. (2006). Chatterjee VK, O'Rahilly S: PPAR gamma and human metabolic disease.
  5. (2004). Cheung NW: C-reactive protein levels following acute myocardial infarction: effect of insulin infusion and tight glycemic control. Diabetes Care
  6. (2006). Cobitz AR: Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial substudy. Curr Med Res Opin
  7. (2003). Dandona P: Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes
  8. (2005). Dandona P: Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment.
  9. (1998). EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol
  10. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem
  11. (2004). Evidence for a potent antiinflammatory effect of rosiglitazone.
  12. (2002). Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation
  13. (2007). G: PPARg activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab
  14. (2000). Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes.
  15. (2006). Hesselink MK: Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.
  16. (2003). I: Overexpressed nuclear factor-kappaB can participate in endogenous Creactive protein induction, and enhances the effects of C/ EBPbeta and signal transducer and activator of transcription-3. Immunology
  17. (2007). Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1alpha and PPARbeta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond)
  18. (2001). Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab
  19. (2004). Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue.
  20. (1992). Interleukin 1 and tumor necrosis factor signal transduction mechanisms: potential targets for pharmacological control of inflammation.
  21. (2003). Koenig W: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation
  22. (2005). M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med
  23. (2007). Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. Genome Biol
  24. (2002). Metabolic effects of interleukin6 in human splanchnic and adipose tissue.
  25. (2001). MW: The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med
  26. (2005). N: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol
  27. (2002). Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis
  28. (2005). Plasma volume measurement in septic patients using an albumin dilution technique: comparison with the standard radio-labelled albumin method. Intensive Care Med
  29. (2003). PPAR gammadependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Biochem Biophys Res Commun
  30. (1996). PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J
  31. (2001). R: PPAR-g dependent and independent effects on macrophage gene expression in lipid metabolism and inflammation.
  32. (2003). Rabelink TJ: Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol
  33. (2001). Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA
  34. (1998). RM: PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell
  35. (2006). S: NF-kappaB and the immune response. Oncogene
  36. (2003). Schonbeck U: Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation
  37. (2001). Staels B: Peroxisome proliferator-activated receptors in inflammation control.
  38. (2007). Stalenhoef AF: The role of TNF-{alpha} in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.
  39. (2001). Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.
  40. (2000). Taniguchi T: Tcell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature
  41. (2005). Tsao PS: Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res
  42. (1993). WC: NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.